← Search & browse all drugs

quingestanol

G03AC04

Forms & Strengths

Oral tablets: 0.3 mg

Adult Dosing

Oral contraception: 0.3 mg daily continuously or as prescribed by regional regimen
Administer at the same time each day without interruption

Pediatric Dosing

Safety and efficacy established only after menarche
Not indicated for pre-menarchal pediatric patients

Indications

Hormonal contraception (progestin-only)
Prevention of pregnancy

Mechanism of Action

Progestin receptor agonist
Suppresses ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis
Increases cervical mucus viscosity to impede sperm penetration
Alters endometrium to inhibit blastocyst implantation

Contraindications

Known or suspected pregnancy
Active or past history of venous thromboembolism
Known or suspected sex hormone-sensitive malignancies
Active liver disease or severe hepatic impairment
Undiagnosed abnormal uterine bleeding
Hypersensitivity to quingestanol or any component of the formulation

Adverse Reactions

Irregular uterine bleeding or spotting
Amenorrhea
Headache
Weight changes
Mood changes including depression
Nausea
Breast tenderness

Drug Interactions

CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) decrease progestin efficacy and increase risk of pregnancy
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase plasma concentrations
Antidiabetic agents: Progestins may impair glucose tolerance, requiring adjustment of anti-diabetic therapy

Curated Content: Needs Vetting Before Put to Clinical Use